newsfilter
← Latest News
GlobeNewswire·

Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides